In other news, Leronlimab is mentioned as potentia
Post# of 148185
Meanwhile, the CCR5 antagonists, such as the small molecular reagents like maraviroc and the humanized monoclonal anti-CCR5 antibody leronlimab, have achieved the primary endpoints in phase 3 clinical studies on HIV, and therefore could be considered for therapeutic repurposing in PDAC (Pancreatic ductal adenocarcinomas).
This is where the $$$ is cancer, HIV, NASH, Alzheimer’s, etc.